| Botulinum toxin type A reduces histamine-induced itch and vasomotor responses in human skin. | |
| | |
MedLine Citation:
|
PMID: 19624547 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Clinical evidence has revealed the antipruritic effect of botulinum toxin type A (BoNT/A). BoNT/A is believed to be effective against itch as it inhibits the release of acetylcholine as well as some other substances that may be involved in itch. OBJECTIVES: To investigate the effect of subcutaneous administration of BoNT/A on experimentally histamine-induced itch in human skin. METHODS: In this double-blind, placebo-controlled study, 14 healthy men (mean +/- SD age 26.3 +/- 2.6 years) received BoNT/A (Botox; Allergan, Irvine, CA, U.S.A.; 5 U) and isotonic saline on the volar surface of either forearm. Histamine prick tests were performed four times at the treatment sites (before treatment, and days 1, 3 and 7 after treatment). The itch intensity (as rated on a 0-10 visual analogue scale), itch area, neurogenic inflammation (visible flare area), blood flow (laser Doppler) and cutaneous temperature (thermographic images) were measured over the course of the trials. RESULTS: BoNT/A reduced the histamine-induced itch intensity (F(1,39) = 30.2, P < 0.001) and itch area (F(1,39) = 8.8, P = 0.011) compared with saline at all time points after treatment. The duration of itch was also shorter for BoNT/A-treated areas (F(1,39) = 19.4, P < 0.001), with a peak effect at day 7. The flare area was smaller in the BoNT/A-treated arm compared with the saline-treated arm at all time points after treatment (F(1,39) = 15.4, P = 0.002). Findings from blood flow (F(1,26) = 177.3, P < 0.001) and temperature measurements (F(1,26) = 27.6, P < 0.001) clearly showed the suppressive effect of BoNT/A on vasomotor reactions, with the maximal effect on days 3 and 7. CONCLUSIONS: BoNT/A reduced the itch intensity, blood flow and neurogenic inflammation in response to the histamine prick test in human skin. The findings could be applicable in the treatment of some pruritic conditions that can be difficult to treat with conventional treatments. |
| | |
Authors:
|
P Gazerani; N S Pedersen; A M Drewes; L Arendt-Nielsen |
Related Documents
:
|
4187 - Histamine h2-receptors in the human peripheral circulation. 1486967 - Effects of inspiratory resistance, inhaled beta-agonists and histamine on canine trache... 3604177 - Effect of microfiltration on the histamine levels in stored human blood. 7681267 - Basophil histamine release induced by anti-ige and concanavalin a. relation to the tota... 21555347 - Fdg pet/ct early dynamic blood flow and late standardized uptake value determination in... 17533857 - Photocatalytic degradation of two volatile fatty acids in an annular plug-flow reactor;... |
Publication Detail:
|
Type: Journal Article; Randomized Controlled Trial Date: 2009-05-11 |
Journal Detail:
|
Title: The British journal of dermatology Volume: 161 ISSN: 1365-2133 ISO Abbreviation: Br. J. Dermatol. Publication Date: 2009 Oct |
Date Detail:
|
Created Date: 2009-09-28 Completed Date: 2010-03-11 Revised Date: 2010-08-05 |
Medline Journal Info:
|
Nlm Unique ID: 0004041 Medline TA: Br J Dermatol Country: England |
Other Details:
|
Languages: eng Pagination: 737-45 Citation Subset: IM |
Affiliation:
|
Center for Sensory-Motor Interaction, Department of Health Sciences and Technology, Aalborg University, DK-9220 Aalborg, Denmark. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Antipruritics / administration & dosage* Botulinum Toxin Type A / administration & dosage* Dermatitis / drug therapy Double-Blind Method Histamine Humans Laser-Doppler Flowmetry Male Prospective Studies Pruritus / chemically induced, drug therapy* Skin / blood supply, drug effects* Skin Tests Thermography Vasoconstriction / drug effects* |
| Chemical | |
Reg. No./Substance:
|
0/Antipruritics; 0/Botulinum Toxin Type A; 51-45-6/Histamine |
| Comments/Corrections | |
Comment In:
|
Br J Dermatol. 2010 Aug;163(2):424-6
[PMID:
20346021
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Quality of life in patients with epidermolysis bullosa.
Next Document: A study of mitochondrial DNA D-loop mutations and p53 status in nonmelanoma skin cancer.